Abstract
Several tumors exhibit pH gradient reversal, with acidification of extracellular pH (pHe) and alkalinization of intracellular pH (pHi). The pH gradient reversal is evident even during the preliminary stages of tumorigenesis and is crucial for survival and propagation of tumors, irrespective of their pathology, genetics and origins. Moreover, this hallmark seems to be present ubiquitously in all malignant tumors. Based on these facts, we propose a new emerging hallmark of cancer “pH gradient reversal”. Normalizing pH gradient reversal through inhibition of various proton transporters such as Na+-H+ exchanger (NHE), Vacuolar-type H+-ATPase (V-ATPase), H+/K+-ATPases and carbonic anhydrases (CAs) has demonstrated substantial therapeutic benefits. Indeed, inhibition of NHE1 is now being regarded as the latest concept in cancer treatment. A recent patent deals with the utilization of cis-Urocanic acid to acidify the pHi and induce apoptosis in tumors. Another patent reports therapeutic benefit by inhibiting Lactate Dehydrogenase - 5 (LDH-5) in various cancers. Several patents have been formulated by designing drugs activated through acidic pHe providing a cancer specific action. The purpose of this review is to analyze the available literature and help design selective therapies that could be a valuable adjunct to the conventional therapies or even replace them.
Keywords: Apoptosis, cancer, migration, pH, proliferation, tumor invasion.
Recent Patents on Anti-Cancer Drug Discovery
Title:pH Gradient Reversal: An Emerging Hallmark of Cancers
Volume: 10 Issue: 3
Author(s): Mohit Sharma, Madhusudan Astekar, Sonal Soi, Bhari S. Manjunatha, Devi C. Shetty and Raghu Radhakrishnan
Affiliation:
Keywords: Apoptosis, cancer, migration, pH, proliferation, tumor invasion.
Abstract: Several tumors exhibit pH gradient reversal, with acidification of extracellular pH (pHe) and alkalinization of intracellular pH (pHi). The pH gradient reversal is evident even during the preliminary stages of tumorigenesis and is crucial for survival and propagation of tumors, irrespective of their pathology, genetics and origins. Moreover, this hallmark seems to be present ubiquitously in all malignant tumors. Based on these facts, we propose a new emerging hallmark of cancer “pH gradient reversal”. Normalizing pH gradient reversal through inhibition of various proton transporters such as Na+-H+ exchanger (NHE), Vacuolar-type H+-ATPase (V-ATPase), H+/K+-ATPases and carbonic anhydrases (CAs) has demonstrated substantial therapeutic benefits. Indeed, inhibition of NHE1 is now being regarded as the latest concept in cancer treatment. A recent patent deals with the utilization of cis-Urocanic acid to acidify the pHi and induce apoptosis in tumors. Another patent reports therapeutic benefit by inhibiting Lactate Dehydrogenase - 5 (LDH-5) in various cancers. Several patents have been formulated by designing drugs activated through acidic pHe providing a cancer specific action. The purpose of this review is to analyze the available literature and help design selective therapies that could be a valuable adjunct to the conventional therapies or even replace them.
Export Options
About this article
Cite this article as:
Sharma Mohit, Astekar Madhusudan, Soi Sonal, S. Manjunatha Bhari, C. Shetty Devi and Radhakrishnan Raghu, pH Gradient Reversal: An Emerging Hallmark of Cancers, Recent Patents on Anti-Cancer Drug Discovery 2015; 10 (3) . https://dx.doi.org/10.2174/1574892810666150708110608
DOI https://dx.doi.org/10.2174/1574892810666150708110608 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Mouse In Cancer Research Past, Present, Future
Current Genomics Recent Advances of Poly(ether-ether) and Poly(ether-ester) Block Copolymers in Biomedical Applications
Current Drug Metabolism Differential Action of Phytochemicals on Platelet Apoptosis: A Biological Overview
Current Medicinal Chemistry Dendritic Cell Vaccine and Cancer Treatment: New Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Short-Term Intra-Nasal Erythropoietin Administration with Low Sialic Acid Content is without Toxicity or Erythropoietic Effects
Current Neurovascular Research Antioxidant Evaluation of Heterocyclic Compounds by Cytokinesis-Block Micronucleus Assay
Mini-Reviews in Medicinal Chemistry Topical Antimicrobials for Burn Wound Infections
Recent Patents on Anti-Infective Drug Discovery Can PPARγ Ligands Be Used in Cancer Therapy?
Current Medicinal Chemistry - Anti-Cancer Agents P2X Receptors, Sensory Neurons and Pain
Current Medicinal Chemistry Exploring the Role of Asp1116 in Selective Drug Targeting of CREBcAMP- Responsive Element-binding Protein Implicated in Prostate Cancer
Combinatorial Chemistry & High Throughput Screening Novel Hexahydropyridoindole Derivative as Prospective Agent Against Oxidative Damage in Pancreatic βCells
Medicinal Chemistry Chiral Kinase Inhibitors
Current Topics in Medicinal Chemistry The Promise of Plant Polyphenols as the Golden Standard Skin Anti-Inflammatory Agents
Current Drug Metabolism Cancer Rehabilitation: Recommendations for Integrating Exercise Programming in the Clinical Practice Setting
Current Cancer Therapy Reviews Fluoroquinolones Prophylaxis of Bacterial Infections in Neutropenic Patients: Time to Re-Evaluate
Current Cancer Therapy Reviews Recent Advances in Pretargeted Radioimmunotherapy
Current Medicinal Chemistry Hydroxypyridinone Derivatives: A Fascinating Class of Chelators with Therapeutic Applications - An Update
Current Medicinal Chemistry Nanocrystal Technology in the Delivery of Poorly Soluble Drugs: An Overview
Current Drug Delivery Therapeutic Potential of Photochemically Active Metal Complexes based on Interaction with Enzymes
Current Topics in Medicinal Chemistry Biomedical Applications of Glycoconjugates
Mini-Reviews in Medicinal Chemistry